Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index; 124 of the 302 sources its claims cite were checked for support.

Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits

Open access
Brunner, Emily, Chen, Chwen-Yuen A., Klein, Tracy, Maust, Donovan, Mazer-Amirshahi, Maryann, Mecca, Marcia, Najera, Deanna, Ogbonna, Chinyere, Rajneesh, Kiran F., Roll, Elizabeth, Sanders, Amy E., Snodgrass, Brett, VandenBerg, Amy, Wright, Tricia, Boyle, Maureen, Devoto, Amanda, Framnes-DeBoer, Sarah, Kleykamp, Bethea, Norrington, Janette, Lindsay, Dawn, Clinical Guideline Committee (CGC) Members, Brunner, Emily, Chen, Chwen-Yuen A., Klein, Tracy, Maust, Donovan, Mazer-Amirshahi, Maryann, Mecca, Marcia, Najera, Deanna, Ogbonna, Chinyere, Rajneesh, Kiran F., Roll, Elizabeth, Sanders, Amy E., Snodgrass, Brett, VandenBerg, Amy, Wright, Tricia, ASAM Staff and Contractors, Boyle, Maureen, Devoto, Amanda, Framnes-DeBoer, Sarah, Kleykamp, Bethea, Norrington, Janette, Lindsay, Dawn · 2025 · Journal of General Internal Medicine

Abstract

Description: The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings. Methods: The guideline was developed following modified GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review. Recommendations: Key takeaways included the following: Clinicians should engage in ongoing risk–benefit assessment of BZD use/tapering, clinicians should utilize shared decision-making strategies in collaboration with patients, clinicians should not discontinue BZDs abruptly in patients who are likely to be physically dependent and at risk of withdrawal, clinicians should tailor tapering strategies to each patient and adjust tapering based on patient response, and clinicians should offer patients adjunctive psychosocial interventions to support successful tapering.

Overview

CoChat Summary

## TL;DR

This 2025 ASAM-led joint clinical practice guideline gives evidence-informed and consensus-based recommendations for tapering benzodiazepines when risks outweigh benefits. It emphasizes patient-centered, shared decision-making; gradual, individualized dose reductions; and special considerations for opioids, substance use disorders, psychiatric disorders, pregnancy, and older adults.

## Key findings

  • The guideline’s systematic literature review identified 57 relevant articles, but few directly addressed the core questions; therefore, most recommendations are based on clinical consensus, and 3 recommendation statements are based on low-quality evidence from 10 studies.
  • For tapering, clinicians should generally start with 5% to 10% dose reductions, and the taper should typically not exceed 25% every 2 weeks; the guideline also notes that tapering may take a year or more for long-term users.
  • In a retrospective cohort of 353,576 US commercial claims patients, discontinuing benzodiazepines over 6 months was associated with 1.6 times higher mortality risk than continued use, but the guideline cautions that the reason for discontinuation and taper speed were not measured.
  • For adjunctive support, a Cochrane review found moderate-quality evidence that CBT during tapering improved discontinuation at 1 month and 3 months; a meta-analysis of brief primary-care interventions found higher discontinuation at 6 months (RR 2.73) and 12 months (RR 3.41).
  • In inpatient phenobarbital protocols, one case series of 310 patients reported 27% sedation, 17% self-discharge, 1% delirium, and no falls or seizures; another chart review of 355 patients reported no seizures, falls, or sedation and 5% self-discharge.

## Methods

  • Design: Joint clinical practice guideline developed by ASAM and partner societies using modified GRADE methodology, a clinical consensus process, a systematic literature review, targeted supplemental searches, and external stakeholder review.
  • Sample/data: The review considered adults using one or more benzodiazepines for at least 2–4 weeks, including those with benzodiazepine use disorder; the systematic review identified 57 relevant articles.
  • Analysis: The guideline used PICO-formulated clinical questions, GRADE for evidence-based recommendations, and a modified Delphi process for consensus statements when evidence was lacking.

## Limitations

  • Stated in the paper: The paper repeatedly notes a paucity of evidence on benzodiazepine tapering; few studies directly answered the core questions, and many recommendations are consensus-based rather than evidence-based.
  • Stated in the paper: There were no direct trials comparing tapering strategies for many key questions, and several recommendations rely on limited or low-quality evidence.
  • Evident from the text: Much of the evidence comes from outpatient settings, retrospective studies, or heterogeneous interventions, so generalizability to all settings and patient groups appears limited (as indicated by the guideline’s emphasis on individualized care and uncertain evidence).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11606-025-09499-2

Cites

206 of 206 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Determining whether and where to taper
Figure 1 Determining whether and where to taperCC BY · PubMed Central
Figure 2 Outpatient taper management
Figure 2 Outpatient taper managementCC BY · PubMed Central

Verification

Claims the paper makes

96 Valid · 7 Not valid · 82 Not checked · 113 Own results and interpretations

165 more claims · 59 with their cited sources checked

Create a free account to see all 298 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 62
  • Probably not a substantial claim. 78
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 206 references

Research works printed but not linked: 12

  1. Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002.
  2. Horowitz M, Taylor DM. Chapter 3: Safe Deprescribing of Benzodiazepines and Z-drugs. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. WILEY Blackwell; 2024.
  3. European Monitoring Centre for Drugs and Drug Addiction. New benzodiazepines in Europe - a review. Luxembourg: Publications Office of the European Union; 2021.
  4. Dikeos DG, Soldatos CR. The pharmacotherapy of insomnia: efficacy and rebound with hypnotic drugs. Prim Care Companion J Clin Psychiatry. 2002;4(Suppl 1):27-32.
  5. Aronson JK ed. Meyler’s Side Effects of Drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th ed. Elsevier; 2016.
  6. Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002.
  7. Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry. 2003;182:498-504. https://doi.org/10.1192/bjp.182.6.498 · DOI · Paper page
  8. Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.
  9. Lähteenmäki R, Puustinen J, Vahlberg T, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77(6):975-985. https://doi.org/10.1111/bcp.12294 · DOI · Paper page
  10. Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002.
  11. Barros VV, Opaleye ES, Demarzo M, et al. Effects of mindfulness-based relapse prevention on the chronic use of hypnotics in treatment-seeking women with insomnia: a randomized controlled trial. Int J Behav Med. 2022;29(3):266-277. https://doi.org/10.1007/s12529-021-10002-4 · DOI
  12. Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16(5):424-431. https://doi.org/10.1089/bfm.2020.0259 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., Sanders, A. E., Snodgrass, B., VandenBerg, A., Wright, T., Boyle, M., Devoto, A., Framnes-DeBoer, S., Kleykamp, B., Norrington, J., Lindsay, D., Clinical Guideline Committee (CGC) Members, Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., Sanders, A. E., Snodgrass, B., VandenBerg, A., Wright, T., Contractors, A. S. A., Boyle, M., Devoto, A., Framnes-DeBoer, S., Kleykamp, B., Norrington, J., & Lindsay, D.
Venue
Journal of General Internal Medicine
Published
2025-06-17
Volume
40
Issue
12
Pages
2814-2859
ISSN
  • 0884-8734 (ISSN-L)
  • 1525-1497
OpenAlex
W4411388475
Cited by
51
References
206
Citations by year
2026: 41 · 2025: 10
FWCI
30.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of General Internal Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
Food and Drug Administration (U01FD007804)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
benzodiazepine tapering, benzodiazepine withdrawal, benzodiazepine dependence, risk-benefit assessment, shared decision-making, physical dependence, psychosocial interventions, drug discontinuation
MeSH terms
Drug Tapering, Benzodiazepines, Humans, Substance Withdrawal Syndrome, Risk Assessment, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. https://app.cochat.ai/papers/10.1007/s11606-025-09499-2
The paper
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., Sanders, A. E., Snodgrass, B., VandenBerg, A., Wright, T., Boyle, M., Devoto, A., Framnes-DeBoer, S., Kleykamp, B., Norrington, J., . . . Lindsay, D. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-025-09499-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.